Cargando…
How should we use convalescent plasma therapies for the management of COVID-19?
Convalescent plasma (CP) from blood donors with antibodies to severe acute respiratory syndrome coronavirus 2 may benefit patients with COVID-19 by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune immunoglobulin preparations. Optimal product characteri...
Autores principales: | Wood, Erica M., Estcourt, Lise J., McQuilten, Zoe K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992504/ https://www.ncbi.nlm.nih.gov/pubmed/33202419 http://dx.doi.org/10.1182/blood.2020008903 |
Ejemplares similares
-
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know
por: Arepally, Gowthami M., et al.
Publicado: (2021) -
Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma
por: Carbone, Antonino, et al.
Publicado: (2023) -
Anticoagulation in hospitalized patients with COVID-19
por: Baumann Kreuziger, Lisa, et al.
Publicado: (2022) -
VEXAS syndrome
por: Grayson, Peter C., et al.
Publicado: (2021) -
The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022)